{"groups":[{"description":"Waldenstrom's Macroglobulinemia Patients","id":"FG000","title":"All WM Patients"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A phase II study using thalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naïve to either agent.","recruitmentDetails":"Patients with Waldenstrom's Macroglobulinemia"}